Cargando…
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedica...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692919/ https://www.ncbi.nlm.nih.gov/pubmed/34976214 http://dx.doi.org/10.7150/thno.67375 |
_version_ | 1784619035707572224 |
---|---|
author | Huang, Yue Hsu, Jessica C. Koo, Hyun Cormode, David P. |
author_facet | Huang, Yue Hsu, Jessica C. Koo, Hyun Cormode, David P. |
author_sort | Huang, Yue |
collection | PubMed |
description | Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities. |
format | Online Article Text |
id | pubmed-8692919 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-86929192022-01-01 Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle Huang, Yue Hsu, Jessica C. Koo, Hyun Cormode, David P. Theranostics Review Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities. Ivyspring International Publisher 2022-01-01 /pmc/articles/PMC8692919/ /pubmed/34976214 http://dx.doi.org/10.7150/thno.67375 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Huang, Yue Hsu, Jessica C. Koo, Hyun Cormode, David P. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title_full | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title_fullStr | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title_full_unstemmed | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title_short | Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle |
title_sort | repurposing ferumoxytol: diagnostic and therapeutic applications of an fda-approved nanoparticle |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692919/ https://www.ncbi.nlm.nih.gov/pubmed/34976214 http://dx.doi.org/10.7150/thno.67375 |
work_keys_str_mv | AT huangyue repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle AT hsujessicac repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle AT koohyun repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle AT cormodedavidp repurposingferumoxytoldiagnosticandtherapeuticapplicationsofanfdaapprovednanoparticle |